New blood thinner aims to prevent clots after knee surgery
NCT ID NCT06825416
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called SHR-2004 to prevent dangerous blood clots in people undergoing elective total knee replacement. Over 1,100 adults participated, receiving either SHR-2004 or a standard blood thinner. The goal was to see if SHR-2004 could reduce clots in the legs or lungs while keeping bleeding risks low.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-2004 injection
What this could lead to
If it works, SHR-2004 could offer a new option to prevent blood clots after knee replacement, potentially reducing the risk of deep vein thrombosis and pulmonary embolism.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The main risk is bleeding, as with any blood thinner. It may not prove safer or more effective than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF ARTERIAL AND VENOUS THROMBOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fourth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, 100048, China
-
Xiangya Hospital, Central South University
Changsha, Hunan, 410008, China